XOMA 3AB, a Novel Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase 1 Clinical Testing
BERKELEY, Calif., May 3, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that the National Institute of Allergy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback